Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. - Wikidata - wikimedia - TriplyDB

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

http://www.wikidata.org/entity/Q37639264

about

Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis A Framework for Understanding the Emerging Role of Corticolimbic-Ventral Striatal Networks in OCD-Associated Repetitive Behaviors Treatment-refractory anxiety; definition, risk factors, and treatment challenges Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Obsessive-compulsive disorder in children and adolescents The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.Exercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy Data Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience Management of obsessive-compulsive disorder.Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder.Clinical practice guidelines for Obsessive-Compulsive Disorder.Treatment response, symptom remission, and wellness in obsessive-compulsive disorder Commonly asked questions in the treatment of obsessive-compulsive disorder.Pharmacological treatment of obsessive-compulsive disorder Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial.Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy.Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India.Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior.Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.Benefits of CBT for OCD in pregnancy Multidimensional Approaches for A Case of Severe Adult Obsessive - Compulsive Disorder.Transcranial direct current stimulation for treatment-resistant obsessive-compulsive disorder: report on two cases and proposal for a randomized, sham-controlled trial.The effect of treatment on quality of life and functioning in OCD.ORBITOFRONTAL THICKNESS AS A MEASURE FOR TREATMENT RESPONSE PREDICTION IN OBSESSIVE-COMPULSIVE DISORDER.A pilot randomized controlled trial of time-intensive cognitive-behaviour therapy for postpartum obsessive-compulsive disorder: effects on maternal symptoms, mother-infant interactions and attachment.Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders

P2860

Q21999508-1B396788-AF83-4B6B-8BDE-BF6691CB254A Q26770749-5050D700-4D87-4387-83AC-599DD0E07F79 Q26798229-729ABA6C-370B-4D08-AD4F-7B66FAF0F9B2 Q27009995-2FD8A787-58CA-43F9-8FAD-23CFA938F7B8 Q27020941-DD3918AB-9704-4B91-B605-9EE4EB284DAC Q30371641-2DD9EE7D-DC8B-41E9-9D22-8C51EC4FFFC4 Q30382252-2FB2C340-7CD6-4981-8F42-3884F63B60BB Q30883311-BE4A194B-E939-42C2-A460-2EFCA760FA3B Q34019896-8EB514A5-1F35-44FF-878F-00912E031644 Q35555514-EC31C27F-197C-4D10-B118-C42B11307BD1 Q35697831-9D556FE5-20E3-4A8E-B941-5F9CCC7645E9 Q35914688-3087AA84-B7BD-44E1-89BD-EC358394121F Q36068947-07589F30-29E2-4235-ADAA-E2C0D54D6669 Q36077216-989DD47A-60AE-47B3-888E-9A78AB7CBB28 Q37140673-795942A0-54E4-44D5-87D1-79F5F897EC7E Q37468737-D8306469-08AF-4CD7-8826-3F426CBABF4C Q37482171-7B8C018E-FB72-4456-AE58-E1E0C9416309 Q37643043-0A910999-D6B1-4B64-87E8-1620EB052AC7 Q37649278-106E7B99-0BF7-4D65-956C-6F5CCA8822C4 Q38174158-7BBBEF06-AAB1-4799-9BFF-61ABBDAF4A67 Q38242548-DBF5E8B5-1199-4D6D-B065-E663A0A14010 Q38722310-135B1178-B076-4794-85F5-AE58CF6E003D Q38820484-D3F71C0E-83F7-493C-8C9D-69CBA4C15B67 Q39254757-7E061510-E018-4CB1-AF81-834C8A5C1542 Q39389604-5249B4C3-DA89-4EB2-9383-669E7406D000 Q39516686-B8D42658-3E21-481B-AB13-D798F8AA8F3A Q40200443-99705BDA-55DF-417B-92AC-9D6A7D3581DC Q41144882-E3C15984-C70A-48AE-B3CD-B923ABB2B7EC Q42571026-5AF1FBD0-DD05-45FB-86CF-4F583E9589AA Q47152738-4A9317DE-E990-43D5-BFDA-ACD10A591924 Q47618978-0ABF14A8-3C7A-4723-ACDC-B37DC17C0945 Q47622292-A9C6FDB5-1174-4AEC-977A-5730CDE300AF Q48150470-DA7BDD57-88C4-4366-9149-4A2C8695F6DE Q50923986-B9F59FA5-181C-4455-BB26-276B0CA58A82 Q58780376-63B16920-6685-42F6-AF33-35DF8724050B

P2860

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

http://www.wikidata.org/entity/Q37639264

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@en

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@nl

type

label

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@en

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@nl

prefLabel

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@en

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@nl

P1433

Q37639264-0DBCDC82-19D2-470F-BBD7-E7AADBCF0AE8

P1476

Q37639264-8A424F5B-8718-4689-8F72-7D78B446DC28

P2093

Q37639264-20471B9F-2715-41DE-9528-9B3D778E9888

Q37639264-2D98276C-0F7F-48E1-BF0F-523D3191313F

Q37639264-42535609-8BD7-4D34-AC0F-C59F63F4AEE0

Q37639264-69CA1825-9859-4E6C-B4D4-C36E58B77820

Q37639264-6C866074-0385-4E38-90B4-D3FB006F7DBB

Q37639264-86252756-039B-480B-9381-0A51C8428D32

Q37639264-982E1236-86E3-46A5-BA90-3EA8CEF9B54E

Q37639264-C65CE771-9B69-4313-BA79-0B2B0B6CF9C8

Q37639264-C716D78F-0409-4E2D-B3A6-4DFC1D2ADB75

Q37639264-DFC70239-8733-4B0E-86B8-1B2671ADCF99

P2860

Q37639264-0032DD80-6DB3-432E-B9E7-CEC26067FDEE

Q37639264-098126FD-6FC7-4F53-8813-DB044789CFB8

Q37639264-181C9F76-43EE-4A16-9BE0-A4BD9F7BF188

Q37639264-273CDCBF-C801-4C3E-8D2E-68698D380F95

Q37639264-2CC0DA74-1A25-4368-B09F-A2659C0B9E29

Q37639264-32DE23A5-97D8-4D82-B005-306D6EB48009

Q37639264-36434382-1FFC-4D63-85BC-11D0A35429C8

Q37639264-37B70071-55E0-41DE-AC0A-12B5E61BED95

Q37639264-3AD9472E-AE7B-471B-A790-357DF2AD57FA

Q37639264-46F0A314-C73C-46E7-84FF-78A38F87BB77

P304

Q37639264-B47C0D25-12A8-4B8F-9191-EE5832007AC2

P31

Q37639264-360F9D68-C7C6-4D52-A748-D3682E20C9DB

P356

Q37639264-763E9528-5733-49C4-B2B6-1CC22AF3C32B

P407

Q37639264-BD89FB0A-388C-4B2F-A7E2-B993A6529FED

P433

Q37639264-723D93F0-D683-4FCF-BD0E-3CB450697EF5

P478

Q37639264-70319AB8-7015-435A-8483-6CE3E32AD8EE

P50

Q37639264-159ED75F-B9A5-4D15-8CAF-10184969B782

Q37639264-29FFE8E6-8DC5-4611-81BC-8A2AED96E42E

Q37639264-76BF44D3-39B3-41E0-A556-C088D821C59A

Q37639264-850C5131-8289-43AC-9B64-24F73C075EEB

P577

Q37639264-1799125B-4954-4CE7-ADB9-08540B8BAA81

P5875

Q37639264-FBE60689-18B5-486B-8471-85FE15B3EB7F

P698

Q37639264-29C2058E-A4F5-4CCE-889C-657EB5594B82

P921

Q37639264-d7d518c6-4912-49f9-ab94-c44bb589677d

P932

Q37639264-1401ADA1-F8FD-492C-AABE-74F6274AAD14

P356

JAMAPSYCHIATRY.2013.1932

P1433

JAMA Psychiatry

P1476

Cognitive-behavioral therapy v ...... : a randomized clinical trial.

@en

P2093

Anthony Pinto

http://www.w3.org/2001/XMLSchema#string

Carmen P McLean

http://www.w3.org/2001/XMLSchema#string

Chang-Gyu Hahn

http://www.w3.org/2001/XMLSchema#string

Donna Vermes

http://www.w3.org/2001/XMLSchema#string

Edna B Foa

http://www.w3.org/2001/XMLSchema#string

Helen Blair Simpson

http://www.w3.org/2001/XMLSchema#string

James Bender

http://www.w3.org/2001/XMLSchema#string

Jamie Weaver

http://www.w3.org/2001/XMLSchema#string

Michael J Maher

http://www.w3.org/2001/XMLSchema#string

Michael R Liebowitz

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine

Practice guideline for the treatment of patients with obsessive-compulsive disorder

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

The Barnes Akathisia Rating Scale--revisited.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity.

Patient preferences for obsessive-compulsive disorder treatment.

P304

1190-1199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAPSYCHIATRY.2013.1932

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan D. Huppert

Carolyn Rodriguez

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256500192

http://www.w3.org/2001/XMLSchema#string

P698

24026523

http://www.w3.org/2001/XMLSchema#string

P921

P932

3955365

http://www.w3.org/2001/XMLSchema#string